Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-Year results of a prospective pilot study

British Journal of Ophthalmology

Volumn 93, Issue 2, 2009, Pages 150-154

  Chan, W M ^a,b,c   Lai, T Y Y ^a   Liu, D T L ^b   Lam, D S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOPHTHALMITIS; EYE EXAMINATION; EYE FUNDUS; EYE INFLAMMATION; EYE PHOTOGRAPHY; EYE TOXICITY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MYOPIC CHOROIDAL NEOVASCULARIZATION; MYOPIC FOVEOSCHISIS; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; REFRACTION ERROR; RETINA FOVEA; RETINA TEAR; RETREATMENT; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; DEGENERATIVE MYOPIA; DRUG ADMINISTRATION; DRUG EFFECT; INJECTION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; VITREOUS BODY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS; MIDDLE AGED; MYOPIA, DEGENERATIVE; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 60849097561     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.145797     Document Type: Article

References (25)

1. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-81.
2. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol 2003;87:570-3.
3. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia. A comparison between age groups. Ophthalmology 2002;109:712-9.
4. Chan WM, Ohji M, Lai TY, et al. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 2005;89:1522-8.
5. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 2001;108:841-52.
6. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 2003;110:667-73.
7. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003;87:173-6.
8. Chan WM, Lai TY, Wong AL, et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathologic myopia: a pilot study. Br J Ophthalmol 2007;91:174-9.
9. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005;89:1368-70.
10. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
11. Spaide RF, Laud K, Fine HF, et al. Intravitral bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
12. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
13. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 2007;91:157-60.
14. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 2007;91:161-5.
15. Mandal S, Venkatesh P, Sampangi R, et al. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 2007;17:620-6.
16. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-12.
17. Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-6.
18. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastastic colorectal cancer. N Engl J Med 2004;350:2335-42.
19. Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007;143:977-83.
20. Adan A, Mateo C, Navarro R, et al. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:1180-6.
21. Schadlu R, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 2008;145:875-8.
22. Bhatnagar P, Freund KB, Spaide RF, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 2007;27:897-902.
23. Finger RP, Issa PC, Ladewig M, et al. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Br J Ophthalmol 2008;92:483-7.
24. Parodi MB, Da Pozzo S, Ravalico G. Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol Scand 2007;85:50-4.
25. Chen YS, Lin JY, Tseng SY, et al. Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up. Retina 2007;27:839-45.